New-Onset Acute Interstitial Lung Disease After Treatment With Erlotinib in a Patient With Metastatic Squamous Cell Carcinoma of the Lung

作者：Taj Asma^*; Kanjwal Shaffi; Hammersley Jeffrey R

来源：American Journal of Therapeutics, 2011, 18(1): E19-E21.

DOI：10.1097/MJT.0b013e3181c2df83

• Erlotinib
• Tarceva
• ILD

Erlotinib is a Human Epidermal Growth Factor Receptor Type 1/tyrosine kinase (EGFR) inhibitor, which is used for non-small-cell lung cancer treatment. Erlotinib usually has a favorable safety profile however; adverse events such as interstitial lung disease (ILD) have been reported in pivotal studies. ILD usually occurs weeks to months after initiating therapy with Erlotinib. We report a case of Erlotinib induced ILD presenting within 5 days of initiating treatment with Erlotinib.

• 出版日期2011-1